Aeglea Biotherapeutics Inc. (NASDAQ:AGLE) rose 13.1% during mid-day trading on Wednesday . The company traded as high as $4.76 and last traded at $4.75, with a volume of 55,940 shares. The stock had previously closed at $4.20.

A number of equities research analysts have commented on the stock. Wells Fargo & Co. assumed coverage on shares of Aeglea Biotherapeutics in a research report on Monday, May 2nd. They issued an “outperform” rating on the stock. BMO Capital Markets assumed coverage on shares of Aeglea Biotherapeutics in a research report on Monday, May 2nd. They issued an “outperform” rating and a $19.00 price objective on the stock. Finally, Needham & Company LLC assumed coverage on shares of Aeglea Biotherapeutics in a research report on Monday, May 9th. They issued a “buy” rating and a $18.00 price objective on the stock.

The company’s 50 day moving average price is $5.73 and its 200 day moving average price is $7.28. The stock’s market cap is $63.70 million.

Aeglea Biotherapeutics (NASDAQ:AGLE) last released its quarterly earnings results on Friday, May 20th. The company reported ($7.10) EPS for the quarter, missing the consensus estimate of ($0.42) by $6.68. On average, analysts anticipate that Aeglea Biotherapeutics Inc. will post ($2.35) earnings per share for the current year.

Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.